Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH – Get Rating) COO Jeff Shaner purchased 9,000 shares of the stock in a transaction dated Thursday, May 19th. The shares were acquired at an average cost of $2.90 per share, with a total value of $26,100.00. Following the acquisition, the chief operating officer now directly owns 1,221,952 shares in the company, valued at approximately $3,543,660.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
AVAH traded down $0.05 on Friday, reaching $2.88. The stock had a trading volume of 509,296 shares, compared to its average volume of 539,943. The firm has a 50-day moving average of $3.64 and a 200-day moving average of $5.41. Aveanna Healthcare Holdings Inc. has a fifty-two week low of $2.09 and a fifty-two week high of $13.00. The company has a market capitalization of $532.03 million and a price-to-earnings ratio of -5.54. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 1.84.
Aveanna Healthcare (NASDAQ:AVAH – Get Rating) last released its quarterly earnings results on Monday, March 28th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.01). Aveanna Healthcare had a negative net margin of 5.70% and a positive return on equity of 8.90%. The company had revenue of $414.07 million during the quarter, compared to the consensus estimate of $420.19 million. Sell-side analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.36 EPS for the current fiscal year.
A number of equities analysts have recently commented on AVAH shares. Bank of America cut Aveanna Healthcare from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $10.00 to $5.50 in a report on Tuesday, March 29th. Deutsche Bank Aktiengesellschaft lowered their price target on Aveanna Healthcare from $12.50 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 30th. Raymond James lowered their price target on Aveanna Healthcare from $12.00 to $8.00 and set a “strong-buy” rating for the company in a report on Thursday, March 31st. Stephens lowered their price target on Aveanna Healthcare from $11.50 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, March 30th. Finally, Credit Suisse Group lowered their price target on Aveanna Healthcare from $12.00 to $9.50 and set an “outperform” rating for the company in a report on Wednesday, March 30th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aveanna Healthcare has an average rating of “Buy” and a consensus target price of $8.90.
About Aveanna Healthcare (Get Rating)
Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals.
- Get a free copy of the StockNews.com research report on Aveanna Healthcare (AVAH)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.